171 related articles for article (PubMed ID: 25331625)
21. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
Storey RF; Gurbel PA; Ten Berg J; Bernaud C; Dangas GD; Frenoux JM; Gorog DA; Hmissi A; Kunadian V; James SK; Tanguay JF; Tran H; Trenk D; Ufer M; Van der Harst P; Van't Hof AWJ; Angiolillo DJ
Eur Heart J; 2020 Sep; 41(33):3132-3140. PubMed ID: 31994703
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y
Liu C; Zhang Y; Chen W; Lu Y; Li W; Liu Y; Lai X; Gong Y; Liu X; Li Y; Chen X; Li X; Sun H; Yang J; Zhong D
Eur J Pharm Sci; 2019 Jan; 127():151-160. PubMed ID: 30326264
[TBL] [Abstract][Full Text] [Related]
23. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
[TBL] [Abstract][Full Text] [Related]
25. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
Merali S; Wang Z; Frost C; Meadows-Shropshire S; Hawthorne D; Yang J; Seiffert D
Platelets; 2023 Dec; 34(1):2222846. PubMed ID: 37394920
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects.
Park JY; Kim KA; Ryu JH; Lee GH; Jeon SH; Kim JS
Int J Clin Pharmacol Ther; 2010 Apr; 48(4):259-69. PubMed ID: 20353747
[TBL] [Abstract][Full Text] [Related]
27. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Teng R; Mitchell PD; Butler KA
Eur J Clin Pharmacol; 2013 Mar; 69(3):477-87. PubMed ID: 22922682
[TBL] [Abstract][Full Text] [Related]
29. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
31. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
32. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study.
Kubica J; Adamski P; Buszko K; Barańska M; Sikora J; Marszałł MP; Sobczak P; Sikora A; Kuliczkowski W; Fabiszak T; Kubica A; Jilma B; Alexopoulos D; Navarese EP
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):139-148. PubMed ID: 30689800
[TBL] [Abstract][Full Text] [Related]
33. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects.
Teng R; Butler K
J Clin Pharm Ther; 2012 Dec; 37(6):704-11. PubMed ID: 22747575
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers.
Kim TE; Kim BH; Kim J; Kim KP; Yi S; Shin HS; Lee YO; Lee KH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2249-57. PubMed ID: 19922896
[TBL] [Abstract][Full Text] [Related]
35. Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation.
Richardson A; Sakariassen KS; Meyer JP; Alberts P; Sorensen AS
Eur J Clin Pharmacol; 2013 Mar; 69(3):459-65. PubMed ID: 22815050
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics and pharmacokinetics of a novel, low-dose, soft-gel capsule of acetylsalicylic acid in comparison with an oral solution after single-dose administration to healthy volunteers: a phase I, two-way crossover study.
Loprete L; Leuratti C; Scarsi C; Radicioni M
Clin Drug Investig; 2014 Jan; 34(1):19-25. PubMed ID: 24132773
[TBL] [Abstract][Full Text] [Related]
37. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
[TBL] [Abstract][Full Text] [Related]
39. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
40. Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects.
Ufer M; Huynh C; van Lier JJ; Caroff E; Fischer H; Dingemanse J
Xenobiotica; 2020 Apr; 50(4):427-434. PubMed ID: 31322041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
